Literature DB >> 9779018

Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system.

B V Taylor1, G Y Oudit, P G Kalman, P Liu.   

Abstract

Both passive and active cigarette smoking increase the risk of cardiovascular disease, the leading cause of death in Western industrialized nations. The prevalence of smoking as a major cardiovascular risk factor has been well characterized over the past 30 years. The two demographic groups of particular concern are women and the young. The relationship between active tobacco smoking and increased risk of coronary artery disease (stable and unstable angina, acute myocardial infarction or sudden death), cerebrovascular disease (cerebral infarction, and cerebral and subarachnoid hemorrhage), peripheral arterial disease (large and small vessel) and aortic aneurysm has been well established in numerous longitudinal and cross-sectional epidemiological and basic science studies. More recently, passive smoking has been shown to represent an important risk factor for coronary artery disease. Smoking can elicit both acute and chronic cardiac and vascular events due to the multiplicity of mechanisms involved: hematological, neurohormonal, metabolic, hemodynamic, molecular genetic and biochemical pathways. Smoking cessation can result in both the inhibition of progression and the regression of pathophysiological changes, improving morbidity and mortality among chronic smokers. The incidence of coronary artery and cerebrovascular diseases in former smokers decreases by 50% two to three years following cessation, but a small long term excess risk persists. Smoking as a cardiovascular risk factor and the clinical cardiovascular features associated with active and passive smoking are discussed, and a pathophysiological framework to explain the association between cigarette smoking and cardiovascular disease is provided.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9779018

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  16 in total

1.  Prevalence of patients continuing to smoke after vascular interventions.

Authors:  Afshin Assadian; Romana Rotter; Christian Senekowitsch; Ojan Assadian; Georg W Hagmüller; Michael Kunze
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

2.  Sustainability of a parental tobacco control intervention in pediatric practice.

Authors:  Jonathan P Winickoff; Emara Nabi-Burza; Yuchiao Chang; Susan Regan; Jeremy Drehmer; Stacia Finch; Richard Wasserman; Deborah Ossip; Bethany Hipple; Heide Woo; Jonathan Klein; Nancy A Rigotti
Journal:  Pediatrics       Date:  2014-10-20       Impact factor: 7.124

Review 3.  Regulation of feeding-associated peptides and receptors by nicotine.

Authors:  M D Li; S L Parker; J K Kane
Journal:  Mol Neurobiol       Date:  2000 Aug-Dec       Impact factor: 5.590

4.  Implementation of a parental tobacco control intervention in pediatric practice.

Authors:  Jonathan P Winickoff; Emara Nabi-Burza; Yuchiao Chang; Stacia Finch; Susan Regan; Richard Wasserman; Deborah Ossip; Heide Woo; Jonathan Klein; Janelle Dempsey; Jeremy Drehmer; Bethany Hipple; Victoria Weiley; Sybil Murphy; Nancy A Rigotti
Journal:  Pediatrics       Date:  2013-07       Impact factor: 7.124

Review 5.  Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.

Authors:  B V Taylor; G Y Oudit; M Evans
Journal:  Can Fam Physician       Date:  2000-11       Impact factor: 3.275

6.  Nicotine dependence and smoking cessation after hospital discharge among inpatients with coronary heart attacks.

Authors:  Atsuhiko Ota; Yoshio Mino; Hiroshi Mikouchi; Norito Kawakami
Journal:  Environ Health Prev Med       Date:  2002-05       Impact factor: 3.674

7.  Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly.

Authors:  A Mazza; A C Pessina; A Pavei; R Scarpa; V Tikhonoff; E Casiglia
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

8.  A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages.

Authors:  A Amoruso; C Bardelli; G Gunella; F Ribichini; S Brunelleschi
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

9.  Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.

Authors:  A Amoruso; G Gunella; E Rondano; C Bardelli; L G Fresu; V Ferrero; F Ribichini; C Vassanelli; S Brunelleschi
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

10.  European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; W M Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte Op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Int J Behav Med       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.